Gordon Moody

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma.

GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma.

Journal: Nature

Published: February 12, 2025

Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers.

Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 12, 2024

DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies.

DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies.

Journal: Frontiers in immunology

Published: July 21, 2023

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.

Journal: The Journal of clinical investigation

Published: March 09, 2023

Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy.

Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy.

Journal: Cytotherapy

Published: September 20, 2021

Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.

Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 05, 2020

Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere.

Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere.

Journal: Journal of medicinal chemistry

Published: November 19, 2019

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Journal: Cancer discovery

Published: April 09, 2018

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.

Journal: PloS one

Published: December 21, 2016

Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.

Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.

Journal: International journal of cancer

Published: March 02, 2016

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 15, 2014

IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.

IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.

Journal: The Journal of endocrinology

Published: February 05, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026